U.S. Officials Warn Of “Pandemic” Avian Influenza And Urgent Need For Cell-Based Vaccines, HepaLife Technologies Inc.'s Primary Target

BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) today announced that a US Government report issued last week by the Department of Health and Human Services (HHS) has reiterated warnings of the Avian Flu’s pandemic threat, and among its response recommendations, urged cell-culture-based influenza vaccine production, HepaLife’s primary application for its patented ‘PBS-1’ cell line.